

China Focus® Conference Facilitates Agreement Between Bayer & Systems Oncology for Investigative Breast Cancer Treatment

Under the terms of the agreement, Bayer will be responsible for developing and commercializing ERSO globally.

HOUSTON, TEXAS, UNITED STATES, October 21, 2020 /EINPresswire.com/ -- Attendees of China Focus® conference, Bayer and Systems Oncology, LLC, signed an exclusive license agreement for investigational breast cancer treatment approach ERSO earlier this month.

Under the terms of the agreement, Bayer will be responsible for developing and commercializing ERSO globally. Systems Oncology will receive an upfront payment of US\$25 million and is eligible to receive payments from Bayer upon achievement of certain development, and commercialization milestones totaling US\$345 million, as well as royalties on future global net sales.

As attendees of China Focus®, MyBioGate's flagship conference series, Bayer and Systems Oncology met for the first time at the event during J.P. Morgan Week 2019. After 20 months of dialogue, positive results were achieved.

"We are very pleased to contribute to the cooperation between the two sides," said Miao Guo Smith, Vice President of Operations and spokesperson for MyBioGate. "We are glad to see the fruition of our years of hard work, and we further believe in the value China Focus® brings to healthcare."

China Focus® conference series brings together investors, pharmaceutical leaders, and innovators from China and around the world for an exclusive partnering event designed to inspire, educate and foster cross-border investment and collaboration in leading biopharma innovations. Since 2018 China Focus® has been held in Philadelphia, Boston, San Francisco,

The logo for China Focus, featuring the words "CHINA FOCUS" in white, bold, sans-serif capital letters. The letter "O" in "FOCUS" is replaced by a red circle. The logo is centered on a black rectangular background.

Germany, and Vienna, attracting more than 1700+ participating attendees, 130+ presenting companies, and 600+ projects worldwide. It has become an important conference for cross border collaboration between China and the rest of the world.

According to Guo, China Focus® will be delivered as virtual events this year due to the impact of COVID-19. The 3-day online partnering conference will continue to bring together investors, pharma leaders, and innovators from China and worldwide. Attendees can create their schedules to plan 1-on-1 meetings with preferred partners through the online system.

Following the successful China Focus® last year, MyBioGate has received a vast amount of positive feedback and increasing interest from companies worldwide.

"We look forward to having China Focus® Virtual providing our clients with a more efficient and convenient experience during this special period. We believe that the conference will help more companies achieve their cross-border collaboration goals."

For more information, please visit <https://events.mybiogate.com/>.

###

FORWARD-LOOKING STATEMENTS

This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as "may," "will," "should," "expect," "anticipate," "project," "estimate," "intend," "continue" or "believe" or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

ABOUT MYBIOGATE

MyBioGate is a premier cross-border healthcare consulting firm serving Biotech and Medtech clients, and the Chinese pharmaceutical companies and investors. The company offers marketing, strategy, and execution support to help healthcare innovation grow by taking advantage of China's huge market potential. We help innovative companies with China-landing services and identify reliable Chinese investors and partners. MyBioGate is committed to linking

healthcare innovations in China and overseas. Its China Focus® conferences, Global Healthcare Innovation Competitions, and roadshows to China provide innovative companies which intend to enter the China market with platforms for exposure to potential investors and partners.

Contact Details:

Feier Chen
Manager of Marketing

7707 Fannin Street
Ste. 200
Houston, TX 77054
United States

Phone: (832) 497-2220

Email: [feier.chen at mybiogate.com](mailto:feier.chen@mybiogate.com)

Source: MyBioGate, Inc.

Feier Chen
MyBioGate, Inc.
+1 832-497-2220
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/528908819>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.